MML Investors Services
WST icon

MML Investors Services’s West Pharmaceutical WST Stock Holding History

MML Investors Services’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.23M Buy
9,008
+1,935
+27% +$592K 0.01% 1241
2026
Q1 		$1.77M Sell
7,073
-5,265
-43% -$1.31M ﹤0.01% 1388
2025
Q4 		$3.39M Sell
12,338
-1,264
-9% -$346K 0.01% 1080
2025
Q3 		$3.57M Sell
13,602
-5,104
-27% -$1.24M 0.01% 1004
2025
Q2 		$4.09M Sell
18,706
-2,355
-11% -$503K 0.01% 885
2025
Q1 		$4.71M Buy
21,061
+819
+4% +$226K 0.02% 750
2024
Q4 		$6.63M Buy
20,242
+1,725
+9% +$543K 0.02% 596
2024
Q3 		$5.56M Buy
18,517
+437
+2% +$134K 0.02% 644
2024
Q2 		$5.96M Buy
18,080
+3,135
+21% +$1.11M 0.02% 587
2024
Q1 		$5.91M Sell
14,945
-1,407
-9% -$520K 0.02% 571
2023
Q4 		$5.76M Buy
16,352
+3,157
+24% +$1.12M 0.03% 542
2023
Q3 		$4.95M Buy
13,195
+662
+5% +$256K 0.03% 541
2023
Q2 		$4.79M Buy
12,533
+678
+6% +$242K 0.03% 552
2023
Q1 		$4.11M Sell
11,855
-482
-4% -$141K 0.03% 526
2022
Q4 		$2.9M Sell
12,337
-5,875
-32% -$1.39M 0.02% 677
2022
Q3 		$4.48M Sell
18,212
-1,486
-8% -$453K 0.03% 475
2022
Q2 		$5.96M Sell
19,698
-2,854
-13% -$929K 0.05% 372
2022
Q1 		$9.26M Buy
22,552
+2,429
+12% +$951K 0.07% 294
2021
Q4 		$9.44M Buy
20,123
+1,826
+10% +$786K 0.07% 286
2021
Q3 		$7.77M Buy
18,297
+260
+1% +$110K 0.06% 310
2021
Q2 		$6.48M Buy
18,037
+2,229
+14% +$736K 0.05% 336
2021
Q1 		$4.45M Buy
15,808
+3,286
+26% +$940K 0.04% 395
2020
Q4 		$3.55M Buy
12,522
+1,291
+11% +$362K 0.04% 402
2020
Q3 		$3.09M Buy
11,231
+334
+3% +$88.4K 0.04% 382
2020
Q2 		$2.48M Buy
10,897
+3,592
+49% +$706K 0.03% 429
2020
Q1 		$1.11M Buy
7,305
+1,551
+27% +$239K 0.02% 591
2019
Q4 		$865K Buy
5,754
+566
+11% +$82.4K 0.01% 766
2019
Q3 		$736K Buy
5,188
+324
+7% +$44.6K 0.01% 804
2019
Q2 		$609K Buy
4,864
+1,141
+31% +$135K 0.01% 926
2019
Q1 		$410K Buy
3,723
+17
+0.5% +$1.77K 0.01% 1108
2018
Q4 		$363K Buy
3,706
+694
+23% +$75.3K 0.01% 1074
2018
Q3 		$372K Buy
+3,012
New +$338K 0.01% 1168

Other funds holding WST

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return
RP
Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return
BTCPP
Border to Coast Pensions Partnership Leeds, United Kingdom $6.78B AUM 31.6% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

MML Investors Services's WST Position: Q2 2026 in Review

MML Investors Services increased its West Pharmaceutical (WST) stake by 27% in Q2 2026, buying an estimated $592K and bringing the position to 9,008 shares worth $3.23M. The position accounts for 0.01% of the portfolio, ranked #1241.

MML Investors Services first reported a position in WST in Q3 2018 and has held it in 32 quarters since. The position peaked at $9.44M in Q4 2021. 427 funds tracked by Wall St. Rank hold WST as of Q2 2026.

  • MML Investors Services held 9,008 shares of West Pharmaceutical worth $3.23M as of Q2 2026.
  • MML Investors Services bought 1,935 West Pharmaceutical shares in Q2 2026, an estimated $592K.
  • West Pharmaceutical made up 0.01% of MML Investors Services's portfolio in Q2 2026, its #1241 holding.
  • MML Investors Services first reported a position in West Pharmaceutical in Q3 2018 and has held it in 32 quarters since.
  • MML Investors Services's West Pharmaceutical position peaked at $9.44M in Q4 2021.
  • 427 funds tracked by Wall St. Rank held West Pharmaceutical as of Q2 2026.

Based on MML Investors Services's 13F filing for Q2 2026, filed 7 Aug 2026.